Verseon Corporation Verseon presents anticancer agents at BIO-Europe
08 November 2017 - 6:00PM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
08 November 2017
Press release November 8, 2017
Verseon Corporation
("Verseon" or the "Company")
Verseon presents anticancer agents for multidrug resistant
tumors at BIO--Europe 2017
Fremont, Calif.-Verseon, a technology-based pharmaceutical
company employing a computer-driven platform to develop a diverse
drug pipeline, showcased its anticancer drug candidates at the
BIO-Europe conference in Berlin yesterday. Dr. Anirban Datta,
Director of Discovery Biology, presented preclinical studies across
a range of cancer cell lines, which show that the Company's
compounds may be especially well-suited for the treatment of
multidrug resistant solid tumors.
One of the most common ways in which cancer cells render
chemotherapies ineffective is by triggering an overproduction of
transport proteins that expel many organic substances, including
drugs. The preclinical data presented at BIO-Europe demonstrate
that Verseon's drug candidates are significantly less susceptible
to this mode of tumor resistance. In vitro studies furthermore show
that the Company's compounds maintain efficacy across multiple cell
lines that are resistant to common chemotherapy agents.
Verseon's drug candidates inhibit microtubule formation by
targeting tubulin. They act against cancer cells by suppressing
blood vessel growth and by interrupting the cell division cycle
preventing mitosis, both proven treatment strategies for cancer.
Lead candidates also show pharmacokinetics suitable for
administration as infusion, an important prerequisite for inclusion
in infusion-based chemotherapy regimens.
"There is an ongoing need for anticancer agents less susceptible
to tumor resistance that can be used in conjunction with existing
and new drugs," said Dr. Datta. "The fact that our tubulin
inhibitors are mostly unaffected by major transporters could change
the standard of care for cancer chemotherapy. In particular, using
transporter overexpression as a biomarker to drive treatment
decisions could lead to more effective precision second-line
therapy."
About Verseon's oncology program
Verseon plans to use its promising class of tubulin inhibitors
to target multidrug resistant cancers. Several drug candidates show
potency in functional and cellular assays. Furthermore, Verseon's
inhibitors maintain their efficacy across multiple
chemotherapy-resistant cancer cell lines and are mostly unaffected
by the overexpression of common transporters, a primary source of
multidrug resistance.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that pairs a proprietary,
computational drug discovery platform with a comprehensive in-house
chemistry and biology workflow to develop novel therapeutics that
are unlikely to be found using conventional methods. The Company is
applying its platform to a growing drug pipeline and currently has
four active drug programs in the areas of anticoagulation, diabetic
macular edema, hereditary angioedema, and oncology. The
anticoagulation program is scheduled to enter phase I clinical
trials in 2018.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMGMRNKGNZM
(END) Dow Jones Newswires
November 08, 2017 02:00 ET (07:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Mar 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024